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Abstract
HLA-DRB1 shared epitope (SE) alleles are the strongest genetic determinants for autoantibody positive rheumatoid arthritis
(RA). One of the key regulators in expression of HLA class II receptors is MHC class II transactivator (CIITA). A variant of the
CIITA gene has been found to associate with inflammatory diseases. We wanted to explore whether the risk variant
rs3087456 in the CIITA gene interacts with the HLA-DRB1 SE alleles regarding the risk of developing RA. We tested this
hypothesis in a case-control study with 11767 individuals from four European Caucasian populations (6649 RA cases and
5118 controls). We found no significant additive interaction for risk alleles among Swedish Caucasians with RA (n=3869,
attributable proportion due to interaction (AP)=0.2, 95%CI: 20.2–0.5) or when stratifying for anti-citrullinated protein
antibodies (ACPA) presence (ACPA positive disease: n=2945, AP=0.3, 95%CI: 20.05–0.6, ACPA negative: n=2268,
AP=20.2, 95%CI: 21.0–0.6). We further found no significant interaction between the main subgroups of SE alleles
(DRB1*01, DRB1*04 or DRB1*10) and CIITA. Similar analysis of three independent RA cohorts from British, Dutch and
Norwegian populations also indicated an absence of significant interaction between genetic variants in CIITA and SE alleles
with regard to RA risk. Our data suggest that risk from the CIITA locus is independent of the major risk for RA from HLA-
DRB1 SE alleles, given that no significant interaction between rs3087456 and SE alleles was observed. Since a biological link
between products of these genes is evident, the genetic contribution from CIITA and class II antigens in the autoimmune
process may involve additional unidentified factors.
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Introduction
Rheumatoid arthritis (RA) is a relatively common disease of
poorly understood aetiology that affects approximately 1% of the
world’s population. Even though the pathophysiology of the
disease is well studied only a limited number of risk factors with
low to moderate effect has been described [1]. Even the strongest
genetic risk factor for RA, the variants in the HLA-DRB1 gene
suggested by the shared epitope (SE) hypothesis [2], confer only a
moderate risk increase for RA, with an odds ratio (OR) of 4–6 in
European Caucasians with regard to anti-citrullinated protein
antibodies (ACPA) positive RA [3,4]. Also, these variations are
quite common in the normal population and their predictive value
is very low. Therefore, the major fraction of RA risk remains
unexplained by existing information and interaction between
known risk factors may account for putative ‘‘missing’’ risk factors.
Indeed, some risk factors for RA has been shown to moderate the
risk for disease in the context of the SE [3,5,6] suggesting that
interactions with SE may play an important role in the
development of RA [7].
We have earlier reported on a variant of the MHC class II
transactivator (CIITA) gene, the 2168A/G promoter SNP
(rs3087456), which associates with inflammatory diseases and also
the expression of CIITA and downstream HLA expression [8].
This association was not consistently replicated in different
populations [9,10]. However, other variants in the CIITA locus
than rs3087456 have been reported in association with autoim-
mune disease [11,12,13] warranting further exploration of this
locus in the context of RA.
Also, due to involvement of HLA class II in RA, the study of
CIITA may reveal more detailed mechanisms of disease develop-
ment, since the protein is known to be a key regulator of MHC
class II expression and therefore may be involved in development
of RA in combination with SE alleles [14,15]. A complete lack of
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complete abolishment of classical MHC class II gene expression
[16]. This is unlikely to be relevant to RA, but less severe changes
in efficiency of CIITA expression might be important for
autoimmunity development and statistical evaluation of genetic
interaction of CIITA and shared epitope alleles may reveal
‘‘missing’’ risk factors.
With this as a background, we set out to define a possible gene-
gene interaction between HLA-DRB1 and the CIITA locus in
development of RA with a study population of 11767 individuals
from four European Caucasian cohorts (6649 RA cases and 5118
controls).
Results
First, we tested the hypothesis of an interactive effect between risk
alleles of HLA-DRB1 SE and rs3087456 for developing of RA in the
Swedish cohort (Cohort I, Table S1). Interaction was estimated
between SE positivity and the risk allele G of rs3087456 in a
homozygous state (GG) [8]. The analysis demonstrated no
significant evidence of interaction in this model (attributable
proportion (AP)=0.2, 95% CI: 20.2–0.5). Since SE is primarily a
risk factor for ACPA positive disease we stratified data according to
ACPAstatusofRAcases.Still,nosignificant evidenceforinteraction
was found, although a tendency was apparent (AP=0.3, 95%CI:
20.05–0.6 for ACPA positivestatus in RA cases, Table1). Similarly,
no significant interaction in additive and multiplicative models was
foundintheBritishandtheDutchcohorts.IntheNorwegiancohort,
however, a significant interaction was detected, both in the total
material and in the ACPA positive RA cases (AP=0.4, 95%CI:
0.03–0.0.7for RA intotaland AP=0.4, 95%CI:0.05–0.7forACPA
positive status in RA cases, Table 1).
To investigate the interaction between HLA-DRB1 SE alleles
and rs3087456 in depth, we used a more detailed description of
the HLA-DRB1 SE alleles by introducing the allelic groups
DRB1*01, DRB1*04 and DRB1*10 as separate risk factors.
These analyses did not reveal an SE subgroup allele specific
interaction with SNP rs3087456 (Table 2).
Since other variants in the CIITA locus have been reported in
association with autoimmune disease we genotyped an additional
22 SNPs across the CIITA locus for the Swedish cohort (Chr16:
10842650–10931606, details for RA association tests of these
SNPs can be found in Tables S2 and S3). Of these 22 SNPs,
including rs3087456, only rs8048002 was significantly associated
with RA after correction for multiple comparisons (ACPA negative
patients, adjusted for 44 test: p=0.013, data submitted elsewhere,
Eike et al. [17]). Rs3087456 was significantly associated with RA
before adjusting for multiple comparisons. To exhaust the
possibility of an interaction between CIITA variants and SE, we
screened all CIITA SNPs for interaction in the Swedish cohort,
using the additive model and two alternative models of
dominance: with the minor and major allele of each SNP. In
these analyses the SNP rs4781019 showed significant interaction
with SE for the ACPA positive subgroup (Table 3, see Table S4 for
detailed results). However, the statistical significance did not hold
after correction for multiple testing (nominal p=0.02 for RA in
total, nominal p=0.03 for ACPA positive RA, significance
threshold for 44 tests is p=0.0011, Bonferroni correction). In
addition the SE interaction with this SNP could not be confirmed
in the independent Norwegian cohort (Table 3.)
Discussion
To assess the combinatorial risk of CIITA and HLA-DRB1 we
have investigated the interaction between HLA-DRB1 SE alleles
and the CIITA 2168A/G polymorphism rs3087456, which was
previously found to be associated with RA [8]. It may be that the
risk for disease is only detectable in certain combinations and also
in certain population. This may be the underlying reason why
rs3087456 has been shown as a genetic risk factor for
immunological disease in some cohorts [8,18,19], but has not
been consistently replicated in other cohorts [20,21,22]. This was
why we set out to define a more specific role of this polymorphism
through genetic interaction with HLA-DRB1 SE alleles. However,
a straightforward interaction model of SE and the rs3087456 G
allele did not reveal significant interaction with regard to RA. In
addition, we performed a detailed analysis with the specific SE
alleles DRB1*01, DRB1*04, DRB1*10 for a more strict allelic
interaction. From this we could conclude that the interaction trend
stayed with DRB1*04 but it did not reach statistical significance.
We observed that the models with DRB1*01 and DRB1*10
showed negative interaction, which led us to remove individuals
with these genotypes from the dataset for a more fair measure of
effect from DRB1*04. This analysis resulted in a significant
interaction, but was not replicated in the Norwegian cohort (Table
S5). A reason for this could be the reduction in size of the dataset
and decreased statistical power.
Although the involvement of SNP rs3087456 was the main
focus of our study, we also addressed genetic variability in this
locus on a broader scale by scrutinizing the CIITA locus for other
putative risk markers in the Swedish RA cohort. In a recent article
addressing the influence of CIITA and HLA-DRB1 in multiple
sclerosis [11], a complex risk relationship between these loci is
presented. The polymorphism rs4774 is described as the major risk
variant in the CIITA locus instead of rs3087456 and with an
increased risk in individuals carrying the DRB1*1501 allele.
Rs4774 is also reported to be associated with the production of
donor-specific HLA antibodies in renal allograft recipients [23].
Indeed, we found some evidence for interaction with another
polymorphism than rs3087456 (rs4781019), but this could not be
replicated in the independent Norwegian cohort.
In general, it is difficult to estimate the statistical power for
measuring low effects of interaction. Also, except for the Swedish
cohort, no particular measures were made to match controls with
the RA patients, which may reduce the power of our study and to
increase genetic heterogeneity of the study. Therefore, to conclude
that an interaction is completely absent between CIITA and HLA-
DRB1 SE alleles in development of RA is not possible. However,
absence of convincing results in four large, independent cohorts
makes it highly unlikely that any strong interaction is present or a
sizeable subgroup of the disease could be explained by this
interaction.
Our study is not directly comparable to association studies of
CIITA in RA, since the major aim was to discover a hypothetical
interaction between CIITA and HLA-DRB1 SE. Even so, this and
previous studies indicates that CIITA plays an ambiguous role for
RA where association signals are difficult to replicate. In a recent
article by Eike et al. (unpublished) [17], an updated meta-analysis
supports the association of CIITA with RA, in particular in the
Scandinavian populations. Also, it seems likely that CIITA is
involved in other autoimmune disease, with multiple sclerosis
being the most pronounced [11,18,24,25]. According to our data,
the previously found association of CIITA variations with RA that
could not be replicated in different Caucasian populations is not
due to a putative interaction between CIITA and SE alleles. Thus,
the missing genetic risk factors for RA remain to be discovered.
To conclude, we did not observe any significant interaction
between rs3087456 or 22 other SNPs in the CIITA locus and HLA-
DRB1 SE alleles with regard to risk of RA.
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Sweden. all Cases/Controls OR 95% C.I. AP (95% C.I.) Add. Mult.
CIITA 168GG SE 0.2(20.2–0.5) P=0.4 P=0.9
No None 571/582 1.0 …
No Any 1655/630 2.7 2.3–3.1
Yes None 41/30 1.4 0.9–2.3
Yes Any 117/33 3.6 2.4–5.4
Sweden. ACPA+
CIITA 168GG SE 0.3(20.05–0.6) P=0.1 P=0.4
No None 222/582 1.0 …
No Any 1205/630 5.0 4.2–6.0
Yes None 11/30 1.0 0.5–2.0
Yes Any 86/33 6.8 4.4–10.5
Norway. all
CIITA 168GG SE 0.4(0.03–0.7) P=0.03 P=0.4
No None 186/682 1.0 …
No Any 533/751 3.8 2.1–3.2
Yes None 14/44 0.9 0.6–2.2
Yes Any 50/43 3.1 2.7–6.6
Norway. ACPA+
CIITA 168GG SE 0.4(0.05–0.7) P=0.02 P=0.7
No None 56/682 1.0 …
No Any 363/751 6.2 4.4–7.9
Yes None 5/44 0.7 0.5–3.6
Yes Any 35/43 5.5 5.9–16.7
UK. all
CIITA 168GG SE 20.2(20.7–0.3) P=0.4 P=0.7
No None 429/638 1.0 …
No Any 1354/529 3.0 3.2–4.5
Yes None 36/57 0.9 0.6–1.5
Yes Any 97/46 2.1 2.2–4.5
UK. ACPA+
CIITA 168GG SE 20.1(20.5–0.3) P=0.7 P=0.6
No None 198/638 1.0 …
No Any 1023/529 5.9 5.1–7.5
Yes None 13/57 1.0 0.4–1.4
Yes Any 79/46 4.3 3.7–8.2
The Netherlands. all
CIITA 168GG SE 20.3(21.4–0.8) P=0.6 P=0.8
No None 136/146 1.0 …
No Any 9/11 2.6 2.2–4.1
Yes None 321/116 1.2 0.4–2.2
Yes Any 20/10 4.3 1.0–4.8
The Netherlands. ACPA+
CIITA 168GG SE 20.4(21.7–1.0) P=0.6 P=0.8
No None 27/146 1.0 …
No Any 2/11 5.9 3.7–9.6
Yes None 127/116 1.4 0.2–4.7
Yes Any 8/10 9.9 1.6–12.0
British. Dutch and Norwegian cohorts.
Results for additive (add.) and multiplicative (mult.) interaction is displayed as significance (P value) of deviation from expected risk given no interaction.
AP=attributable proportion; SE=shared epitope; OR=odds ratio; ACPA+=anti citrullinated protein antibody positive RA patients; CI=confidence interval.
doi:10.1371/journal.pone.0032861.t001
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Description of cohorts
Interaction between HLA-DRB1 SE alleles and rs3087456 in
CIITA was primarily investigated in a cohort consisting of 2520
incidenceRA cases and 1349 matched controls from Swedish EIRA
study, which is described elsewhere [3,26]. The analysis was
repeated in three other cohorts: from UK (1916 cases and 1270
controls), the Netherlands (1260 cases and 346 controls) and
Norway (953 cases and 2153 controls) with overall 11767
individuals in the study (6649 RA cases and 5118 controls). All
RA patients met the American College for Rheumatology 1987
(ACR-87) revised criteria for RA [27]. For the Swedish cohort,
patients were recruited to the study by practioners not responsible
for the study, who after informing registered a verbal consent in the
patients journal. If consent was given, an extensive questionere was
filled in by the patient. Controls were invited by letter and were also
asked to fill in and send back an extensive questionere and to visit
the closest primary care for leaving samples. This active
participation was the foundation for informed consent. All subjects
can at any moment withdraw from the study. This procedure is in
line with the ethical permit and regulation in Sweden. All
individuals in the Dutch, Brittish and Norwegian cohort gave their
written informed consent to participate. The local regional ethical
review boards approved this study (Regionala etikpro ¨vningsna ¨mn-
den i Stockholm, Sweden; The Leiden institutional review board,
Commissie Medische Ethiek, Netherlands; The North-West Multi-
Centre Research Ethics Committee and University of Manchester
Committee on the Ethics of Research on Human Beings, United
Kingdom; Regionale komiteer for medisinsk og helsefaglig
forskningsetikk (REK) sør-øst, Oslo, Norway).
Swedish cohort
Genotyping for Swedish cohort was performed by TaqMan
predesigned genotyping assay (CIITA) (Applied Biosystems, Foster
City, California) and by SSP-PCR (Olerup SSP, Saltsjo ¨baden,
Sweden). The ACPA status was previously identified for all RA
patients by Immunoscan RA (Mark 2, cut-off for positivity
$25 U/ml) enzyme-linked immunosorbent assay (Euro-Diagnos-
tica, Malmo ¨, Sweden).
IntheEIRAstudy,onlyaminornumberofcontrolsweredetected
to be ACPA positive (1.8%, n=24), while controls from other
cohorts were not tested. When stratifying by ACPA status, controls
were always considered as a whole group and not divided in strata.
Dutch cohort
Patient characteristics have been described previously [28]. The
healthy controls were randomely selected by the immunogenetics
and Transplantation Immunology section of the Leiden University
Medical Center.
Genotyping was performed as described for the Swedish cohort.
ACPA status was determined by Immunoscan RA (Mark 2, cut-off
for positivity $25 U/ml) enzyme-linked immunosorbent assay
(Euro-Diagnostica, Malmo ¨, Sweden). HLA typing has been
described elsewhere [29].
British cohort
All subjects were white Caucasians and all patients satisfied
ACR-87 criteria modified for genetic studies [30].
Genotyping for the UK cohort was performed using the Sequenom
MassARRAY iPLEX system in accordance with the manufacturer’s
instructions (www.Sequenom.com). ACPA was tested using the Axis-
Shield DIASTAT kit according to the manufacturer’s instructions
(positivity: concentration .5U / m l ) .T h ep r e s e n c eo fHLA-DRB1 SE
copy number (0, 1 or 2 copies) was detected using a semi-automated
reverse hybridization method (Dynal Biotech, Wirral, UK).
Norwegian cohort
Norwegian RA patients were from the Oslo RA Registry
(ORAR) and the European Research on Incapacitating Disease
and Social Support (EURIDISS) cohorts [31,32]. Healthy Norwe-
gian control samples were collected from the Norwegian Bone
Marrow Donor Registry (NBMDR), Oslo University Hospital,
Rikshospitalet (Controls-1, n=1121) and blood donors recruited at
Oslo University Hospital, Ulleva ˚l (Controls-2, n=1032). An ELISA
kit assay (INOVA Diagnostics, San Diego, California, USA) was
used to measure ACPA concentrations in the RA samples, with a
positivity cut-off defined as levels .25 U/ml. Genotyping of CIITA
SNPs in the Norwegian cohort was performed with TaqMan
predesigned assays. Genotyping for HLA-DRB1 in the Norwegian
RA patients and controls from NBMDR was done by sequence-
based genotyping [33], whereas blood donors were genotyped by
PCR-based sequence-specific oligonucleotide probe system [34].
Statistical analyses
Additive interaction was defined by departure from additivity of
effects originally described by Rothman [35] and was estimated by
Table 2. Summary data of the interaction analysis for HLA-
DRB1 SE allelic groups and SNP rs3087456 for the Swedish
cohort.
Group rs3087456 and: AP CI 95 low CI 95 high P value
All SE (yes/no) 0.2 20.2 0.5 0.5
DRB1*01 20.3 21.2 0.6 0.5
DRB1*04 0.2 20.2 0.6 0.3
DRB1*10 0.05 21.5 1.6 0.9
ACPA+ SE (yes/no) 0.3 20.05 0.6 0.1
DRB1*01 20.2 21.1 0.7 0.7
DRB1*04 0.3 20.1 0.6 0.2
DRB1*10 20.1 22.0 1.8 0.9
Additive interaction is presented as attributable proportion (AP) with 95%
confidence interval (CI). For additional analysis see Table S5. SE=shared
epitope; ACPA+=anti citrullinated protein antibody positive RA patients.
doi:10.1371/journal.pone.0032861.t002
Table 3. Summary data for interaction analysis between CIITA
rs4781019 and HLA-DRB1 SE.
Dominant model Recessive model
Cohort Group AP P value AP P value
Swedish All 0.3 0.02 0.1 0.5
ACPA+ 0.3 0.03 0.1 0.4
Norwegian All 0.04 0.7 0.03 0.8
ACPA+ 20.01 0.9 0.1 0.4
The table presents the best result after analysis of interaction between the CIITA
locus and HLA-DRB1. Dominant and recessive (for the risk allele) genetic models
were tested for each SNP, see Table S4 for complete results. AP=attributable
proportion; SE=shared epitope; ACPA+=anti citrullinated protein antibody
positive RA patients.
doi:10.1371/journal.pone.0032861.t003
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[36]. For each individual, variables were defined for having none,
either or both risk factors. The statistical tool R was used for
logistic regression and estimating ORs for variables and AP was
calculated with 95% confidence intervals (version 2.9.0, http://
www.r-project.org/). This procedure was facilitated by scripts
developed by Kallberg et al., 2006 [37]. Interaction was calculated
between SNP rs3087456 (homozygous for G allele) and HLA-
DRB1 SE alleles defined as any of DRB1*01, DRB1*04 and
DRB1*10. For the other polymorphisms in the CIITA locus both
dominant and recessive models for the risk allele were used. For
calculating multiplicative interaction and performing allelic
association analysis we used the software PLINK (version 1.06,
http://pngu.mgh.harvard.edu/purcell/plink/).
We used Bonferroni correction for multiple testing when
appropriate.
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Table S2 Association analyses of the CIITA locus with
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position in chromosome 16. MAF is short for minor allele
frequency. Plink was used for statistical analysis (http://pngu.mgh.
harvard.edu/purcell/plink/). P-values are unadjusted.
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